Financial Performance - For the year ended December 31, 2023, the company reported total revenue of RMB 24,629,000, a decrease of 2.77% from RMB 25,330,000 in 2022[6]. - The gross profit for the same period was RMB 16,093,000, down 4.84% from RMB 16,914,000 in the previous year[6]. - The company incurred a loss attributable to owners of RMB 5,782,000, compared to a loss of RMB 3,075,000 in 2022, representing an increase in loss of 88.06%[6]. - The total loss before tax for the year was RMB 5,782,000, compared to a loss of RMB 3,075,000 in 2022, reflecting a deterioration in financial performance[22][23]. - The company reported a basic and diluted loss per share of RMB 1.39, compared to RMB 0.76 in 2022, marking an increase in loss per share of 83.55%[6]. - The company reported a basic loss per share of RMB 5,782,000 for the year ended December 31, 2023, compared to RMB 3,075,000 in 2022[37]. - The company recorded a significant increase in trade receivables impairment losses to approximately RMB 1.4 million, compared to approximately RMB 373,000 in the previous year, attributed to the deteriorating repayment ability of distributors due to the economic situation in China[64]. Revenue Segmentation - The revenue from the biopharmaceutical and assisted reproductive products and equipment segment was RMB 24,314,000, representing an increase of 4.91% from RMB 23,177,000 in the previous year[22]. - The health products and supplements segment generated revenue of RMB 315,000, down from RMB 2,153,000, indicating a significant decline of 85.32%[22]. - Sales in the health products and supplements segment dropped significantly to account for only 1.3% of total revenue, down from 8.5% in the previous year due to increased competition and the impact of COVID-19[54]. - Revenue from the in vitro diagnostic reagent business increased by approximately RMB 1.1 million, representing a growth rate of 4.9%[53]. - External customer revenue for China in 2023 was RMB 24,314,000, up from RMB 23,177,000 in 2022, representing a growth of approximately 4.9%[29]. - Total external customer revenue decreased from RMB 25,330,000 in 2022 to RMB 24,629,000 in 2023, a decline of about 2.8%[29]. Expenses and Costs - Research and development expenses for the year were RMB 2,553,000, slightly up from RMB 2,483,000 in 2022, indicating a focus on innovation[6]. - The administrative expenses for the year were RMB 3,287,000, an increase from RMB 2,982,000 in the previous year[22][23]. - Other income for 2023 was RMB 734,000, compared to RMB 884,000 in 2022, reflecting a decrease of approximately 16.9%[32]. - The company reported a gross margin decrease from 66.8% to 65.3%[62]. - The company has established a prudent treasury policy to manage cash reserves and maintain healthy liquidity for future growth opportunities[78]. Assets and Liabilities - The total assets as of December 31, 2023, were RMB 53,436,000, a marginal increase from RMB 53,423,000 in 2022[7]. - The company's cash and cash equivalents stood at RMB 32,935,000, down from RMB 33,303,000 in the previous year, reflecting a decrease of 1.10%[7]. - The net current assets decreased to RMB 40,340,000 from RMB 43,642,000, indicating a decline of 7.00%[7]. - Total liabilities as of December 31, 2023, were RMB 14,296,000, with the biotechnology segment accounting for RMB 6,806,000[25]. - The total trade receivables net of credit loss allowance stood at RMB 9,683,000 in 2023, slightly up from RMB 9,470,000 in 2022[41]. Shareholder Information - The total number of issued shares as of December 31, 2023, was 418,472,000[101]. - Mr. Zhang Shuguang holds 51.0% of the company's shares, totaling 213,256,000 shares[100]. - Major shareholder Crystal Grant holds 209,256,000 ordinary shares and 4,000,000 options, representing 51.0% of total equity[104]. - Wealthy Pride Investment Limited, controlled by Lau Lai Yee, holds 28,800,000 shares, accounting for 6.9% of total equity[104]. - The major shareholders collectively hold a significant portion of the company's equity, indicating strong insider confidence[107]. Corporate Governance and Compliance - The company adheres to the corporate governance code as per GEM listing rules effective from December 31, 2023[89]. - The audit committee has reviewed the consolidated financial statements and confirmed compliance with applicable accounting standards and GEM listing rules[106]. - The financial data presented in the announcement has been agreed upon by the auditors, Zhongshen Zhonghuan CPA Limited[108]. - The company emphasizes the accuracy and completeness of the information provided in the announcement, ensuring no misleading or fraudulent elements[112]. - The company confirmed compliance with the GEM listing rules regarding a minimum public float of 25% since the listing date until the announcement date[96]. Future Plans and Strategies - The company plans to continue focusing on research and development to enhance its product offerings and market position[5]. - The company plans to continue research and development in rapid testing based on immune testing technology, aiming for medical device registration after satisfactory results[57]. - The company aims to enhance its health supplement business by seeking partners and distributors to promote the "Nutronic" brand more effectively[57]. - The company plans to raise funds through share placements, with a maximum of 82 million new shares at HKD 0.105 per share, expected to generate approximately HKD 1.99 million for general operating funds[86]. - A second share placement agreement was established for up to 62 million new shares at HKD 0.096 per share, with an updated price of HKD 0.104 per share, expected to raise approximately HKD 3.18 million[86].
华康生物医学(08622) - 2023 - 年度业绩